Key Drivers
- Cash Rich
- No Revenue
- Ongoing Losses
AIAI Summary
ELVN now looks less like a simple cash-rich biotech and more like a single-asset clinical bet: its strong ~2029 cash runway reduces dilution risk, but the stock's upside now hinges on ELVN-001 proving durable, differentiated efficacy and tolerability ahead of the planned Phase 3 in 2H26, while any delay or weaker expansion data could quickly cap the rerating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Rich
- •No Revenue
- •Ongoing Losses
ELVN has a very strong cash-heavy balance sheet and no debt, but persistent losses, zero revenue, and a premium-to-book valuation mean the stock's case depends more on its cash pile than on operating performance.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Failed rebound
- •Dip buying
ELVN remains in a cautious downtrend over the last month, with lower highs and failed rebounds despite dip-buying near support, and it needs a decisive break above $43.5-$44.0 to signal a reversal.
Brief bounce to $43.56 on 2026-05-13 faded over the next two sessions
Sentiment & News
Key News Insights:
- •Phase 1 growth
- •Strong runway
- •Phase 3 ahead
Enliven Therapeutics reported continued positive ELVN-001 Phase 1 progress, with a larger CML dataset and favorable MMR/safety results supporting its mid-2026 update and second-half 2026 Phase 3 plan, while its $452M cash balance extends runway into 1H29.
Positive clinical momentum and ample cash improve visibility into ELVN-001's development path and support the stock's near-term outlook
Similar Companies in Healthcare
Other companies in the same sector with AI ratings